Leal Therapeutics Doses First ALS Patient with LTX-002
WORCESTER, Mass. | June 23, 2026 Leal Therapeutics has announced that the first patient has been dosed in the...
ALS
Advertisement
CervoMed Secures $10 Million to Advance Brain Disease Pipeline
BOSTON, June 18, 2026 CervoMed Inc., a clinical-stage biotechnology company focused on developing therapies for age-related neurological disorders, has...
Coya Therapeutics Begins Blinded Extension Phase of ALSTARS Trial for COYA 302 in ALS
HOUSTON, Texas, June 8, 2026 Coya Therapeutics, Inc. announced a significant milestone in the ongoing ALSTARS clinical trial, with...
AC Immune Reports Positive Phase 1 ALS Imaging Data for ACI-19626
LAUSANNE, Switzerland, May 22, 2026 AC Immune announced new preliminary Phase 1 data showing that its investigational TDP-43 PET...
AndzonBio2 and Cambridge Partner on Neuroinflammation Therapies
PARIS and CAMBRIDGE, UK, May 13, 2026 AndzonBio2 announced a strategic collaboration with the ALBORADA Drug Discovery Institute (ADDI)...
Advertisements
Corcept Therapeutics Reports ALS Survival Breakthrough
REDWOOD CITY, California, April 30, 2026 Corcept Therapeutics Incorporated announced compelling two-year overall survival data from its Phase 2...
Pixee Medical Knee+ NexSight Wins FDA 510(k) Clearance
BESANÇON, France, April 28, 2026 Pixee Medical has announced that its next-generation augmented reality (AR) surgical navigation system, Knee+...
Taiho Zipalertinib NDA Accepted by FDA for NSCLC
PRINCETON, New Jersey, USA / TOKYO, Japan / CAMBRIDGE, Massachusetts, USA, April 28, 2026 Taiho Oncology, Taiho Pharmaceutical, and...
VectorY Therapeutics Secures EMA and MHRA Approval for VTx-002 Trial
AMSTERDAM, Netherlands & BOSTON, Massachusetts, USA, April 28, 2026 VectorY Therapeutics has announced that it has received authorization from...
ALS Research at Risk from Proposed FY27 Budget Cuts
ARLINGTON, Virginia, United States, April 7, 2026 The ALS Association has issued a strong statement warning that the proposed...
Advertisement
